@article{TCR9451,
author = {Roberto Ferrara and Mario Caccese and Federica Cuppone and Emilio Bria and Giampaolo Tortora and Sara Pilotto},
title = {Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that?},
journal = {Translational Cancer Research},
volume = {5},
number = {Suppl 3},
year = {2016},
keywords = {},
abstract = {Small-cell lung cancer (SCLC) has historically been considered a highly chemo-radiosensitive malignancy, rarely susceptible of surgical resection due to advanced stage presentation with bulky nodal disease and frequent systemic involvement. Actually, surgical series documented SCLC in just 2–3% of patients (1) and, although several randomized trials contributed to define the management of extensive and limited stage SCLC, very few data are available for the early stage, possibly resectable, disease.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/9451}
}